QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
NASDAQ:RGLS

Regulus Therapeutics (RGLS) Stock Forecast, Price & News

$1.33
+0.03 (+2.31%)
(As of 06/1/2023 ET)
Compare
Today's Range
$1.29
$1.35
50-Day Range
$0.79
$1.75
52-Week Range
$0.76
$3.00
Volume
14,921 shs
Average Volume
56,487 shs
Market Capitalization
$25.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Regulus Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
576.7% Upside
$9.00 Price Target
Short Interest
Healthy
1.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.53) to ($1.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

1079th out of 1,980 stocks

Pharmaceutical Preparations Industry

531st out of 978 stocks


RGLS stock logo

About Regulus Therapeutics (NASDAQ:RGLS) Stock

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.

Receive RGLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RGLS Stock News Headlines

Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Regulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Update
See More Headlines

RGLS Price History

RGLS Company Calendar

Last Earnings
3/23/2023
Today
6/01/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:RGLS
CUSIP
75915K10
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+576.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-28,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10.01 million
Book Value
$1.37 per share

Miscellaneous

Free Float
17,861,000
Market Cap
$25.91 million
Optionable
Optionable
Beta
1.56

Key Executives

  • Joseph P. HaganJoseph P. Hagan
    President, Chief Executive Officer & Director
  • Crispina Calsada
    Chief Financial Officer
  • Claire S. Padgett
    Senior Vice President-Clinical Operations
  • Christopher AkerChristopher Aker
    Secretary, Senior Vice President & General Counsel
  • Brian K. Campion
    Vice President-Business Development













RGLS Stock - Frequently Asked Questions

Should I buy or sell Regulus Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RGLS shares.
View RGLS analyst ratings
or view top-rated stocks.

What is Regulus Therapeutics' stock price forecast for 2023?

3 brokers have issued 1-year target prices for Regulus Therapeutics' shares. Their RGLS share price forecasts range from $9.00 to $9.00. On average, they anticipate the company's share price to reach $9.00 in the next year. This suggests a possible upside of 576.7% from the stock's current price.
View analysts price targets for RGLS
or view top-rated stocks among Wall Street analysts.

How have RGLS shares performed in 2023?

Regulus Therapeutics' stock was trading at $1.37 at the beginning of 2023. Since then, RGLS stock has decreased by 2.9% and is now trading at $1.33.
View the best growth stocks for 2023 here
.

Are investors shorting Regulus Therapeutics?

Regulus Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 253,700 shares, an increase of 26.0% from the April 30th total of 201,300 shares. Based on an average daily trading volume, of 67,000 shares, the short-interest ratio is presently 3.8 days. Approximately 1.6% of the shares of the stock are short sold.
View Regulus Therapeutics' Short Interest
.

When is Regulus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our RGLS earnings forecast
.

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc. (NASDAQ:RGLS) released its quarterly earnings results on Thursday, March, 23rd. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.09.

When did Regulus Therapeutics' stock split?

Regulus Therapeutics shares reverse split on the morning of Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Joseph Hagan's approval rating as Regulus Therapeutics' CEO?

2 employees have rated Regulus Therapeutics Chief Executive Officer Joseph Hagan on Glassdoor.com. Joseph Hagan has an approval rating of 49% among the company's employees. This puts Joseph Hagan in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Regulus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regulus Therapeutics investors own include Aduro Biotech (ADRO), Flexion Therapeutics (FLXN), Cytori Therapeutics (CYTX), PTC Therapeutics (PTCT), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Trevena (TRVN).

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

Who are Regulus Therapeutics' major shareholders?

Regulus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%). Insiders that own company stock include Christopher Ray Aker, Denis Drygin, Joseph P Hagan and Paul Edward Walker.
View institutional ownership trends
.

How do I buy shares of Regulus Therapeutics?

Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regulus Therapeutics' stock price today?

One share of RGLS stock can currently be purchased for approximately $1.33.

How much money does Regulus Therapeutics make?

Regulus Therapeutics (NASDAQ:RGLS) has a market capitalization of $25.91 million and generates $10.01 million in revenue each year. The biopharmaceutical company earns $-28,320,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis.

How can I contact Regulus Therapeutics?

Regulus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The official website for the company is www.regulusrx.com. The biopharmaceutical company can be reached via phone at (858) 202-6300 or via email at ccalsada@regulusrx.com.

This page (NASDAQ:RGLS) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -